← Leaderboards
Glen N Barber
Stinginn, Llc
$2,335,814
Attributed
$4,527,099
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2020–24$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,527,099 · 6
By mechanism
R42$2,987,068 · 2
R41$1,540,031 · 4
Top collaborators
- Jeonghyun Ahn4 shared
- Juan Carlos Ramos3 shared
Others in their field
Other Emerging Leaders on “Production”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$451,761,218
- Sonia M Thomas · Research Triangle Institute$451,761,218
- Leonard Freedman · Leidos Biomedical Research, Inc.$239,520,687
- Lynn Briscoe · Leidos Biomedical Research, Inc.$108,384,076
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
Research focus
ProductionCellsProteinsInfectionPreventUniversitiesMouse ModelBarberingImmune SystemClinical TrialsT-LymphocyteFuturePhase I TrialMalignant - DescriptorLaboratoriesMalignant NeoplasmsAdult T-Cell Leukemia/LymphomaInflammatoryEventCollaborationsDesignCytotoxic T-LymphocytesHuman T-Lymphotropic Virus 1Host Defense
Grant awards (8)
Human T Cell Lymphotropic Virus Vaccine Development$999,969
R42 · FY2024 · CA · contact PI
STING Activators as Therapy for Cancer$993,879
R42 · FY2023 · CA · contact PI
Human specific STING agonists for the treatment of cancer$399,812
R41 · FY2023 · CA · contact PI
Human T cell Lymphotropic Virus Vaccine development$288,295
R41 · FY2023 · AI · contact PI
STING Activators as Therapy for Cancer$993,220
R42 · FY2022 · CA · contact PI
Anti-inflammatory Activity of a Systemic STING Inhibitory Non-Nucleotide$300,000
R41 · FY2022 · AI · contact PI
Human T cell Lymphotropic Virus Vaccine development$299,860
R41 · FY2022 · AI · contact PI
STING Activators as Therapy for Cancer$252,064
R41 · FY2020 · CA · contact PI